403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Pharma industry representative collapses in Oval Office
(MENAFN) A pharmaceutical industry representative collapsed in the Oval Office on Thursday as US President Donald Trump announced a new initiative to reduce the cost of popular weight-loss medications.
The man, initially identified by media outlets as Novo Nordisk executive Gordon Finlay, was standing behind Trump when his knees appeared to give way. However, Novo Nordisk — the Danish company that produces Ozempic, Rybelsus, and Wegovy — later denied that the individual was Finlay.
According to Fox News reporter Jacqui Heinrich, who witnessed the incident, Dr. Mehmet Oz, head of the Centers for Medicare and Medicaid Services, quickly assisted the man to prevent injury. Cabinet members raised his legs while reporters were escorted from the room.
White House Press Secretary Karoline Leavitt later told reporters that “the gentleman is okay.”
Earlier in the event, Trump had announced that prices for weight-loss medications such as Ozempic would soon be “much lower.” Executives from Novo Nordisk and Eli Lilly joined the president for the announcement, outlining a deal to make GLP-1 drugs — a class of medications used to treat diabetes and obesity — more affordable.
Under the new plan, branded as TrumpRx, manufacturers will expand access to drugs like Ozempic, Wegovy, and Zepbound through a government website launching next year. Oral GLP-1 medications could start at $149 per month pending FDA approval, while injectable versions will cost $245 per month for Medicare and Medicaid patients prescribed them for approved medical conditions such as diabetes.
The man, initially identified by media outlets as Novo Nordisk executive Gordon Finlay, was standing behind Trump when his knees appeared to give way. However, Novo Nordisk — the Danish company that produces Ozempic, Rybelsus, and Wegovy — later denied that the individual was Finlay.
According to Fox News reporter Jacqui Heinrich, who witnessed the incident, Dr. Mehmet Oz, head of the Centers for Medicare and Medicaid Services, quickly assisted the man to prevent injury. Cabinet members raised his legs while reporters were escorted from the room.
White House Press Secretary Karoline Leavitt later told reporters that “the gentleman is okay.”
Earlier in the event, Trump had announced that prices for weight-loss medications such as Ozempic would soon be “much lower.” Executives from Novo Nordisk and Eli Lilly joined the president for the announcement, outlining a deal to make GLP-1 drugs — a class of medications used to treat diabetes and obesity — more affordable.
Under the new plan, branded as TrumpRx, manufacturers will expand access to drugs like Ozempic, Wegovy, and Zepbound through a government website launching next year. Oral GLP-1 medications could start at $149 per month pending FDA approval, while injectable versions will cost $245 per month for Medicare and Medicaid patients prescribed them for approved medical conditions such as diabetes.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment